Myeloproliferative Neoplasms (MPN)

- CNL/atypical CML
  - IRB#10262: Oral Ruxolitinib for CNL or atypical CML.
- Myelofibrosis
  - IRB#16363: Phase 2 INCB050465 plus Ruxolitinib
  - IRB#15836: Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation
- Non Treatment
  - IRB#15977: National MDS Study (ECOG/ACRIN)

For more information, visit: [http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)